A25 ASSOCIATION OF BIOLOGIC PRESCRIBING FOR INFLAMMATORY BOWEL DISEASE WITH INDUSTRY PAYMENTS TO PHYSICIANS
Notice bibliographique
Résumé
Financial conflicts of interest (FCOIs) between the pharmaceutical industry and physicians have been associated with changes in prescribing behaviour, though the nature of this association in inflammatory bowel disease (IBD) is unknown. To investigate the relationship between the prescribing of biologic medications for IBD and industry payments to physicians from pharmaceutical companies making those medications. We used two US databases from 2013–2015: (1) The Centres for Medicare and Medicaid Services (CMS) Part D prescription claims database, which documents medications prescribed under Medicare; and (2) Dollars for Docs, which lists payments made by pharmaceutical companies to physicians. We identified physicians who prescribed biolgic medications for IBD and recorded industry payments physicians received from companies producing biologic medications in three categories: (1) Education; (2) Food and travel; and (3) other, such as speakers and consulting fees. A linear regression tested the association between payments received by a physician and dollar value of prescriptions written for biologics. A second regression was performed with an additional predictor variable to account for patient volume. 3475 gastroenterologists prescribed IBD biologics from 2013–2015. 3441 (99.0%) received at least one payment from a company producing the biologic medications they prescribed (Table 1). There was a significant association between the prescribing of biologics and the receipt of payments from companies making biologics (p<0.001; R2=6.49% ). For every $1000 in industry payments, there was an associated $2441 increase in prescription claims (95% CI: $2133 to $2748) (Figure 1). When accounting for patient volume, the associated prescription cost was significantly related to the value of industry payments (p<0.001, R2=7.64%). For every $1000 in industry payments, there was an associated $3846 increase in prescription claims (95% CI: $3285 to $4407). The strength of the association was similar for all three types of payments. There is an association between the receipt of industry payments from pharmaceutical companies making biologics for IBD, and the prescribing of those medications. These results highlight a potentially concerning influence of industry on prescribing behaviour. Payments from pharmaceutical companies making biologic medications to physicians with 11 or more associated prescription claims for those biologic medications, from 2013–2015 inclusive * Payment values in US dollars, per prescriber † Consulting fees, speakers’ fees, royalties, honoraria, and gifts SD, Standard deviation Relationship between industry payments and prescriptions for biologic medications. Total payments received by each physician are plotted on horizontal axis, while total cost associated with prescriptions written by each physician is plotted on the vertical axis. Payments are only counted if they are made by a company producing a medication that the receiving physician prescribes. None
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction distillée sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.
Scores Codex et Gemma par catégorie
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,001 | 0,001 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,000 | 0,000 |
| Bibliométrie | 0,000 | 0,000 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,000 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,000 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule tête enseignante, pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».